Logo
Whalesbook
HomeNewsCorporate NewsPremiumStocks
HomeNewsCorporate NewsPremiumStocks

Concord Biotech Ltd

₹ 1,4033.56%
07 Jan 11:18 a.m. – close price
🔗concordbiotech.com•BSE: 543960•NSE: CONCORDBIO
Market Cap₹ 14,677 Cr.
Current Price₹ 1,403
High / Low₹ 2,452
Stock P/E45.7
Book Value₹ 174
Dividend Yield0.75 %
ROCE28.4 %
ROE21.4 %
Face Value₹ 1.00
Sales₹ 1,125 Cr.
OPM39.1 %
Mar Cap₹ 14,677 Cr.

ABOUT

Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.[1]

KEY POINTS

Business Profile[1]Concord Biotech is a pharmaceutical company headquartered in Ahmedabad, Gujarat, specializing in Active Pharmaceutical Ingredients (APIs) and formulations. The company is engaged in development and manufacturing ofniche fermentation-based APIs and finished dosage formulationsfor domestic and international markets.

Also present in buckets:
Aggressive Growth TriggersExcellent ResultsRevenue GuidanceAsset Base ExpansionCapacity Expansion And ProductsJv Partnerships AcquisitionsRevenue Guidance Vs ActualsRed Flags And Poor Performance

Peer Comparision

S.No.NameCurrent Price (Rs.)Price to EarningMarket Capitalization (Rs.Cr.)Dividend yield (%)Net Profit latest quarter (Rs.Cr.)YOY Quarterly profit growth (%)Sales latest quarter (Rs.Cr.)YOY Quarterly sales growth (%)Return on capital employed (%)Sales (Rs.Cr.)OPM (%)Profit after tax (Rs.Cr.)Profit after tax latest quarter (Rs.Cr.)Price to book valueReturn on assets (%)Debt to equity
1.Sun Pharma.Inds.1774.6036.78425785.980.923124.952.5614478.318.9320.2154964.0130.1211543.963117.955.4512.970.07
2.Divi's Lab.6685.0071.34177465.720.45689.0035.102715.0016.1220.4410029.0032.372485.00689.0011.5513.530.01
3.Torrent Pharma.4018.8062.79136014.430.80591.0032.493302.0014.3027.0512248.0032.602166.53600.1716.1013.260.33
4.Cipla1482.0022.01119711.670.871353.373.737589.447.6422.7228349.5725.405441.141351.173.6714.720.01
5.Dr Reddy's Labs1256.8518.17104900.540.641336.807.288828.309.8322.6934310.0024.645772.201347.102.9212.950.16
6.Lupin2204.3023.30100692.200.551484.8373.347047.5124.2321.3024750.6927.254324.631477.925.1412.410.32
7.Mankind Pharma2284.2053.9594292.910.04520.18-22.003697.1620.7715.9813545.6724.121748.55511.516.178.890.55
8.Concord Biotech1402.9045.6614676.570.7562.90-36.27247.06-20.3528.351125.1539.13321.5062.908.0819.090.00
–Median: 150 Co.415.3530.891770.90.1113.0312.32157.210.8414.98582.8715.9644.5513.733.178.60.22

Quarterly Results

Standalone figures in ₹ crores

Dec 2022Dec 2023Dec 2024Jun 2023Jun 2024Jun 2025Mar 2023Mar 2024Mar 2025Sep 2022Sep 2023Sep 2024Sep 2025
Sales
241241244195216204273319430159262310247
Expenses
129135146123135143144185239121143174157
Operating Profit
112106987281611291341903811913791
Other Income
98157101412119681013
Profit before tax
106100996578571261311853011313386
Tax %
26%26%25%25%25%26%26%26%23%26%25%26%26%
Net Profit
797574485843949714222849963
EPS in Rs
7.567.137.084.635.574.078.949.2913.572.148.089.436.01

Profit & Loss

Standalone Figures in ₹ Crores / Yearly

Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales
3404365126177138531,0171,2001,125
Expenses
195256308289439509585693685
Operating Profit
145180205328274344432507440
Other Income
181731142335344451
Interest
111165310
Depreciation
181921285054545464
Profit before tax
144178213313241320409496427
Net Profit
100118169235179238305373322
EPS in Rs
105.66124.48177.65247.44187.7622.7629.1335.6530.73
Dividend Payout %
-0%21%22%-0%3%30%30%25%–

Compounded Profit Growth

10 Years:%
5 Years:19%
3 Years:27%
TTM:-2%

Compounded Sales Growth

10 Years:%
5 Years:19%
3 Years:19%
TTM:4%

Return on Equity

10 Years:%
5 Years:21%
3 Years:21%
Last Year:21%

Stock Price CAGR

10 Years:%
5 Years:%
3 Years:%
1 Year:-38%

Balance Sheet

Standalone figures in ₹ crores

Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
101010101010101010
Reserves
5856737619901,0981,2821,5151,8021,815
Borrowings
229528962321032
Other Liabilities
697211894144191164219194
Total Liabilities
6857639411,1831,3131,5151,6992,0342,021
Fixed Assets
189230240546573593575795790
Gross Block
220.92280.91310.15644.29719.94791.69825.511,095.41–
Accumulated Depreciation
32.2451.2170.5598.08146.97198.71250.20300.73–
CWIP
31914118741732115174
Investments
15122919914274138244335354
Other Assets
343285361477592611668854804
Total Assets
6857639411,1831,3131,5151,6992,0342,021

Cash Flows

Standalone Figures in ₹ Crores / Yearly

Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity
79–155167207246265245
Cash from Investing Activity
-42–-114-195-112-158-155-160
Cash from Financing Activity
-37–-4331-100-85-99-99
Net Cash Flow
0–-13-4312-14

Ratios

Standalone Figures in ₹ Crores / Yearly

Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days
236133131105119117125159
Inventory Days
381310312503434430331286
Days Payable
210112201152185190150135
Cash Conversion Cycle
407331242456368357306310
Working Capital Days
275186159177163153166193
ROCE %
–27%25%32%21%26%28%28%

Shareholding Pattern

Numbers in percentages

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Promoters
44.08%44.08%44.08%44.08%44.08%44.08%44.08%44.08%44.08%
FIIs
7.30%7.00%6.49%7.11%8.10%8.33%9.35%9.10%8.03%
DIIs
8.12%8.40%8.41%10.35%9.82%9.65%9.16%8.85%9.55%
Public
40.50%40.52%41.03%38.46%38.02%37.93%37.41%37.94%38.32%

* The classifications might have changed from Sep'2022 onwards.ℹ️

BSE Announcements AI Summary

Direct from BSE filings, auto-summarised

Concord Biotech Files SEBI Compliance Certificate for Q4 FY26

8th April 2026, 4:22 pm

Concord Biotech Acquires Celliimune Biotech for Cancer Research Advancement

2nd April 2026, 9:17 pm

Concord Biotech Announces Trading Window Closure Ahead of Financial Results

28th March 2026, 12:06 am

Concord Biotech to Host Analyst & Investor Meeting on March 6

26th February 2026, 8:03 pm

Concord Biotech Announces Analyst / Institutional Investor Meeting Schedule with IIFL Capital

20th February 2026, 3:40 pm

Published by Other Websites

External media mentions & references

Jhunjhunwala Portfolio's Healthcare Pivot: 4 Key Stocks Examined

16th April 2026, 6:51 am

US Tariff Threat Hits Indian Pharma Stocks Hard, Index Down 3%

2nd April 2026, 11:10 am

IT, EV Stocks Plunge as Market Hits 52-Week Lows

23rd February 2026, 1:13 pm

Breakout Stocks Surge as RBI Holds Rates; ITC, LIC Lead Gains

7th February 2026, 5:30 pm

Budget STT Hike Sparks Sell-Off: Dalal Street Plunges 1,500 Points

1st February 2026, 4:23 pm

News Articles

Editorial & research coverage

Concord Biotech Stock Sees 'Buy' Rating, 16% Upside Forecast
Concord Biotech Stock Sees 'Buy' Rating, 16% Upside Forecast

6th January 2026, 10:27 am

Pharma Stocks Alert: Antique Reveals Top Picks Amid Shifting Market Dynamics!
Pharma Stocks Alert: Antique Reveals Top Picks Amid Shifting Market Dynamics!

29th December 2025, 11:49 am

Concord Biotech's Profit PLUMMETS 33%, but HUGE Biotech Acquisition & Green Energy Push Could Spark Comeback!
Concord Biotech's Profit PLUMMETS 33%, but HUGE Biotech Acquisition & Green Energy Push Could Spark Comeback!

13th November 2025, 8:51 pm

Documents

Announcements

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

17h - Registrar's certificate dated Jan 05, 2026 confirming dematerialisation for quarter ended Dec 31, 2025.

Closure of Trading Window
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer

24 Dec - Ms. Hina Patel resigns as Company Secretary & Compliance Officer, cessation effective close of business Jan 21, 2026.

Intimation Under Regulation 30(5) Of The SEBI (LODR) Regulations, 2015

18 Dec - Revised KMP list disclosed (Sudhir Vaid, Ankur Vaid, Raviraj Karia, Hina Patel) on 18-Dec-2025.

Announcement under Regulation 30 (LODR)-Change in Management

18 Dec - Appointed Mr. Raviraj Karia as CFO effective December 18, 2025; CA with 23+ years' experience.

Annual Reports

Financial Year 2025

(from bse)

Financial Year 2024

(from bse)

Credit Ratings

Rating update

23 Jul 2025 from icra

Rating update

9 May 2024 from icra

Rating update

10 Apr 2023 from icra

Rating update

7 Apr 2022 from icra

Rating update

4 Feb 2021 from icra

Rating update

30 Jun 2020 from icra

Concalls

Nov 2025

TranscriptPPT

Aug 2025

TranscriptPPT

Jun 2025

TranscriptPPTRecording

Feb 2025

TranscriptPPT

Nov 2024

TranscriptPPT

Aug 2024

TranscriptPPT

Jun 2024

TranscriptPPT

Feb 2024

TranscriptPPT

Nov 2023

TranscriptPPTRecording

Sep 2023

Transcript

Sep 2023

TranscriptPPT

Stock Analysis

Description

  1. Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.

Key Growth Triggers

  1. Full-year FY25 saw strong performance with 18% revenue growth and 21% PAT rise. The company maintains a debt-free status. Key strategic initiatives include international regulatory approvals (EU-GMP, NAFDAC, US FDA), new subsidiaries, an injectable facility ramp-up, and approved acquisitions like Celliimune Biotech, positioning it for future growth. Management reiterates a long-term 25% CAGR growth target.

Order Book

  1. Currently no data available for Order Book.

Key Red Flags

  1. Q1 and Q2 FY26 results showed year-over-year declines in revenue and profit, attributed to operational factors, facility costs, and regulatory delays. Recent changes in Key Managerial Personnel (CFO early retirement, new CFO appointment, Company Secretary resignation) mark a period of transition.

Key Dates To Watch

  1. Imminent announcement of Q3 FY26 financial results and related board meeting.

Corporate Announcements

8th Apr 26
Impact Rating: 3
Concord Biotech Limited has filed its quarterly SEBI (Depositories and Participants) Regulations, 2018 compliance certificate. The company confirmed that no requests for dematerialization or rematerialization of equity shares were received during the quarter ended March 31, 2026.
2nd Apr 26
Impact Rating: 8
Concord Biotech acquired 100% of Celliimune Biotech Private Limited for ₹66.00 lakh (₹0.66 cr) to advance pioneering research in DNA engineering for cancer therapeutics.
27th Mar 26
Impact Rating: 5
Concord Biotech Limited is closing its trading window from April 1, 2026, until 48 hours after its audited financial results for the quarter and year ended March 31, 2026, are declared. This measure aligns with SEBI regulations to prevent insider trading by designated persons and their relatives.
26th Feb 26
Impact Rating: 6
Concord Biotech Limited is set to meet with investors and analysts on March 6, 2026. Hosted by Antique Stock Broking at the company's Ahmedabad plant, the focus will be exclusively on publicly available information.
20th Feb 26
Impact Rating: 2
Concord Biotech Limited will engage with analysts and institutional investors on February 26, 2026, in Mumbai. Discussions will be based on publicly available information.